Global Blood Therapeutics to seek to expand label for sickle cell treatment
June 08, 2020 at 16:16 PM EDT
Global Blood Therapeutics Inc said on Monday it plans to ask U.S. regulators to greenlight the use of its sickle cell treatment, Oxbryta, in children between ages 4 and 11, expanding on an earlier approval for patients 12 and over.